(Q37951994)

25 August 2017

Belinostat: clinical applications in solid tumors and lymphoma (English)

1 reference

25 August 2017

L Rhoda Molife

1

1 reference

25 August 2017

Johann S de Bono

series ordinal

2

1 reference

25 August 2017

language of work or name

English

0 references

publication date

3 November 2011

1 reference

Expert Opinion on Investigational Drugs

25 August 2017

1 reference

25 August 2017

20

1 reference

25 August 2017

12

1 reference

25 August 2017

1723-1732

1 reference

The nucleosome: from genomic organization to genomic regulation

25 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Histone acetylation in chromatin structure and transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Class II histone deacetylases: from sequence to function, regulation, and clinical implication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Medicinal chemistry of sirtuin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Histone deacetylase inhibitors: discovery and development as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Acetylation and deacetylation of non-histone proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

HDAC6 is a microtubule-associated deacetylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Prospects: histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Endothelial-derived tissue factor pathway inhibitor regulates arterial thrombosis but is not required for development or hemostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Microtubules as a target for anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Post-translational modifications regulate microtubule function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Chromatin in need of a fix: phosphorylation of H2AX connects chromatin to DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Biomarkers for predicting clinical responses to HDAC inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.629604

10.1517/13543784.2011.629604

21 January 2018

Identifiers

DOI

1 reference

release_3k2pqrmvyfdybguurydknionfe

25 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3k2pqrmvyfdybguurydknionfe

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference